Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis

NCT00095498 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00095498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00095498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
August 11, 2004
Completion date
April 1, 2007
Enrollment
227 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis